Characteristics of Non-Alcoholic Fatty Liver Disease Patients at Dr. M. Djamil General Hospital Padang (original) (raw)
Related papers
Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome
The Journal of the Association of Physicians of India, 2009
To study the prevalence of NAFLD in those patients attending the routine health checkup and to establish a relationship between NAFLD and metabolic syndrome. All patients attending the health check-up had their blood pressure, height and weight, waist circumference measurements, blood sugars, lipid levels and ultrasound abdomen done. The prevalence of NAFLD among these subjects was determined and the presence of risk factors for metabolic disease in each individual was analysed. A relationship between NAFLD and metabolic syndrome was then established. Of the 1003 people 225 (22.6%) had NAFLD with higher prevalence among males 164/565 (29%) than among females 61/438 (13.9%). In the NAFLD group normal body mass index (BMI) was present in only 49/225 (20%) of the subjects while 119/225 (52.8%) were overweight and 56/225 (24.8%) were obese. Though liver enzymes were normal the mean AST among cases was 37.41 +/- 14.50 and 33.93 +/- 14.15 among controls and the mean ALT was 38.74 +/- 17.9...
Razavi International Journal of Medicine, 2021
Introduction:Our study is assessing the epidemiological aspects of nonalcoholic fatty liver disease (NAFLD) in Iranian population and evaluates the relationship between NAFLD and metabolic syndrome.Methods and Materials:We conducted this cross-sectional study on 145 subjects who were diagnosed with NAFLD and referred to the Gastroenterology clinics of Ghaem Hospital, Mashhad, Iran in the year of 2013. Using ultrasonography method, we diagnosed NAFLD as a fatty liver manifestation in the absence of other liver complications. We used National Cholesterol Education Program Adult Treatment Panel III criteria (ATPIII) as a guideline to establish metabolic syndrome diagnosis.Results:Metabolic syndrome had an overall prevalence of 49.7% among our subjects. The results showed no difference in mean AST and ALT levels between the groups of patients with and without metabolic syndrome. Our results were unable to maintain an association between our targeted liver enzymes (AST and ALT) and diffe...
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021
Background and Aims: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing in Saudi Arabia (SA), but descriptions of the clinical and metabolic characteristics of these patients are limited. The present study aims to fill this gap. Methods: Demographic, clinical, and laboratory data of all NAFLD patients from 2009 to 2019 were retrieved from the Systematic Observatory Liver Disease Registry (SOLID) [n=832 (337 males; 495 females); mean (± standard deviation, SD) age was 42.6±13.6 years; mean body mass index (BMI) was 35.0±9.3kg/m 2 ]. Non-invasive surrogate scores of fibrosis (eg AST to Platelet Ratio Index (APRI), Fibrosis-4 (FIB-4), and NAFLD fibrosis (NFS) scores) were calculated and analyzed. In addition, data from NAFLD patients with normal and high alanine aminotransferase (ALT) were compared using two different methods: the standard laboratory reference range which defines normal as ALT<61 IU/L, and the range proposed by a recent national study which sets upper limits of normal ALT at 33 IU/l for men and 22 IU/l for women. Results: Hyperlipidemia was the most common comorbidity (41.7%), followed by type 2 diabetes mellitus (T2DM) (35.3%) and hypertension (28.4%). Prevalence of advanced fibrosis varied widely across definitions [FIB-4, N=19 (2.5%); APRI, N=21 (2.8%); NFS, N=62 (8.6%)] and exhibited sexual dimorphism with males having worse metabolic characteristics. NAFLD patients with normal ALT were more likely to be older, female, have a lower BMI, and have a higher prevalence of cirrhosis, DM, hypertension, hyperlipidemia, and renal dysfunction. Conclusion: Patients with NAFLD have metabolic characteristics associated with several comorbidities, including NAFLD patients with normal ALT. Mechanistic studies are needed to examine and analyze complex, interactive effects between sex, age, and other factors that may accelerate NAFLD disease progression.
Abstract— Non Alcoholic Fatty Liver Disease is also becoming public health impotance nowadays. So this study was aimed to determine the association of Non Alcoholic Fatty Liver Disease with metabolic syndrome and Cardio-Vascular disease along with assessment of degree of severity of NAFLD with respect to number of components of metabolic syndrome. This study includes a total of 222 subjects were enrolled as per the inclusion/exclusion criteria, out of which 110 cases who had NAFLD with hepatic steatosis on ultrasonography and 112 subjects who did not have NAFLD were considered control. These cases and controls were interrogated and investigated further. Observations were recorded and association of Non Alcoholic Fatty Liver Disease with metabolic syndrome and Cardio-Vascular disease along with assessment of degree of severity of NAFLD with respect to number of components of metabolic syndrome. Statistical methods used were unpaired student’s t-test for continuous variables, Fischer’s and chi-sq test for categorical variables using bivariate analysis by Graph Pad Instat Version 3.10. Risk was assessed in terms of Odd's Ratio. The patients with MS and NAFLD had a higher proportion of CVD compared with those who did not have NAFLD (29.1 vs 18.1 %). This study concludes that NAFLD is significantly associated with MS; most significant with WC, followed by TG and FBS and thus can be considered as hepatic component of MS. This needs more research with large multi-centric prospective studies to evaluate NAFLD as an independent risk factor for CVD.
BMC Gastroenterology
Background: Non-alcoholic fatty liver disease (NAFLD) is mutually and bidirectionally linked with metabolic syndrome (MetS) of which it is both the cause and the consequences. Worldwide, 6.3 to 33% of the general populations are estimated to suffer from the disease with even higher prevalence in the group sharing metabolic co-morbidities. Hence, this study aims to recognize various risk factors including metabolic components and blood parameters to predict the possible incidence of the disease. Methods: Total of 429 (219 NAFLD and 210 control) subjects were conveniently selected for study during the period of 9 months. Diagnosis of non-alcoholic fatty liver disease was done by liver imaging and based on liver enzymes. Assessment of metabolic syndrome was done by International Diabetic Federation (IDF) and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. All biochemical and hematological parameters and liver enzymes were estimated by using standard guideline. Mean comparison of quantitative data in different groups were performed using analysis of variance (one-way ANOVA). Risk estimation of NAFLD associated with each character was verified by Chi-square test. Results: There was significant high levels of body mass index (BMI), waist circumference (WC) and lipid profiles in NAFLD patients in comparison to control population (p < 0.001). Further, according to the NCEP ATP III criteria, 13. 6% of NAFLD were present with MetS where risk estimate was significant (OR = 2.15). Whereas, other criteria (IDF) for MetS showed higher frequency (30.1%) with higher risk (OR = 29.75) for the presence of MetS in NAFLD patients. The change in triglycerides (TG) and HDL-C (high density lipoprotein cholesterol) was also statistically significant in different grades of NAFLD. High risk for NAFLD was associated with existing co-morbid conditions like cardiovascular risk patients (3.18 times) followed by obese patients (1.72 times) and Diabetes Mellitus patients (1.68 times) at a significant level. Conclusion: The result of this study suggests that there is an increased prevalence of all the components of MetS and significant changes in biochemical markers in cases of NAFLD. Timely diagnosis would help in delaying its complications and co-morbidities.
Lipid and Glucose Profile in Non-alcoholic Fatty Liver Disease: A Hospital Based Study
Background: Non-alcoholic fatty liver (NAFLD) is an important cause of chronic liver disease of worldwide distribution. Its prevalence is rapidly increasing in developing countries. In the Kingdom of Saudi Arabia, primary or secondary NAFLD is frequently encountered given that obesity and diabetes mellitus are prevalent. Objectives: The current study assessed the frequency, clinical patterns, status of liver function and lipid profile in patients with NAFLD. Patients and Methods: This observational cross sectional study enrolled patients attending Salman Bin Abdul Aziz University Hospital, Kharj between October, 2012 and December 2014. All patients were invited to complete a structured closed ended dichotomous questionnaire about risk factors of NAFLD. Physical examination, BMI, liver function tests, lipid profile, HOMA-IR, abdominal ultrasound were also performed in all patients. The NAFLD Liver Fat Score and presence of steatosis were used for predicting the NAFLD. The NAFLD fibrosis score was used for staging the NAFLD related fibrosis. Results: Patients with NAFLD constituted 32% of total patients presenting to SAU university hospital. Viral hepatitis, drug-induced liver injury, autoimmune hepatitis, hemochromatosis, and Wilson's disease were excluded in these patients. NAFLD was greatly associated with 38% obese and 41% diabetic patients. Furthermore, 21% patients were also diagnosed with primary NAFLD. Various grades of steatosis were observed in ultrasound which is predominantly found in primary NAFLD. Additionally, patients with primary NAFLD have more elevated lipid profiles, HOMA-IR and liver enzymes. It's worth noting that the NAFLD fibrosis scores are way high in patients with primary NAFLD compared to secondary NAFLD. Conclusion: NAFLD is the most frequent chronic disease among patients attending liver clinic in Salman Bin Abdul Aziz University Hospital. Diabetes, obesity, and unexplained abnormal liver function tests are the striking features of the patients where NAFLD should be suspected. Consistent monitoring of the progression of NAFLD is an essential component for predicting fibrosis in these patients in due course of treatment.
Journal of Medicine, 2015
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a distinct clinicopathologic entity characterized histologically by a spectrum ranging from simple steatosis to steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma (HCC).Objective: To determine the incidenceand identify the risk factors of NAFLD in non-obese patients.Methods: It was a cross sectional study done in Department of gastroenterology, Nuclear Medicine and ultrasound, Radiology and Imaging, Virology, Biochemistry, BSMMU, Dhaka from March 2012 to June 2014. The patients more or equal to 18 years, non-obese were included. In this study total 190 patients were enrolled.Results: Among them 38 patients were with fatty liver and 152 patients without fatty liver on the basis of ultrasonogram. Where 141 were male and 49 were female with mean age was 49.24 + 9.05 years. Among total, 18.9% had diabetes mellitus, 28.4% had dislipidaemia 24.4% had history of hypertension. Total 18.9% patients having history of ...
The natural course of non-alcoholic fatty liver disease
Hepatology Forum, 2020
Background and Aim: The present study aims to describe the characteristics and long-term clinical outcomes of patients with non-alcoholic fatty liver disease (NAFLD). Material and Methods: A total of 1308 individuals with NAFLD were seen in the Liver Diseases Outpatient Clinic. Diagnosis of NAFLD in each case was based on biochemical, radiological and histological criteria, when available. After diagnosis, all NAFLD patients were administered a conventional diet and exercise program. The median follow-up period was 55.3 months. Results: At the time of the diagnosis, the mean age was 50.8±11.3 years, and female gender was slightly predominant (51.4%). The median body mass index was 29.2±4.7 kg/m 2 : 39% were obese. Seventeen percent of the patients had diabetes mellitus, 53% insulin resistance, 60% hyperlipidemia, and 32% hypertension. Median serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase levels were 31 U/L